Physician profile

James Roe

Los Angeles, CA

NPI 1881685956

$411.84

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$55.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Fresenius USA Marketing, INC. $189.44 2021-2024 Velphoro
Otsuka America Pharmaceutical, INC. $61.20 2019
Horizon Therapeutics Plc $40.73 2021-2022
Bayer Healthcare Pharmaceuticals INC. $34.38 2022
Astrazeneca Pharmaceuticals Lp $26.78 2024 Lokelma
Novo Nordisk INC $24.01 2022
Amgen INC. $21.76 2019
Novartis Pharmaceuticals Corporation $13.54 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Roe

$411.84

in general payments reported 2019-2025

Years
2019-2024
Top company
Fresenius USA Marketing, INC.

https://glasscript.com/doctor/312085/james-roe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.